Abstract

BackgroundAspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role in the pathogenesis of AERD. It is still unknown, whether metabolism of AA is comparable between the upper and lower airways as well as between patients with and without NSAR intolerance.ObjectiveWe sought to analyze differences in the expression of cyclooxygenases type 1 and 2 (COX-1, COX-2), arachidonate 5-lipoxygenase (5-LOX) and cysteinyl leukotriene receptor type 2 (hbox {CysLT}_2) in nasal polyps and the bronchial mucosa of patients with aspirin intolerant asthma (AIA, n=23) as compared to patients with aspirin tolerant asthma (ATA, n=17) and a control group with nasal polyps, but without asthma (NPwA, n=15).MethodsTissue biopsies from nasal polyps and bronchial mucosa were obtained during surgical treatment of nasal polyps by endonasal functional endoscopic sinus surgery (FESS) under general anesthesia from intubated patients. Immunohistochemistry was used to analyze the expression of COX-1, COX-2, 5-LOX and hbox {CysLT}_2 in nasal and bronchial mucosa. Categorization into the different patient groups was performed according to the patient history, clinical and laboratory data, pulmonary function and provocation tests, as well as allergy testing.ResultsWe observed a stronger expression of 5-LOX and hbox {CysLT}_2 in submucosal glands of nasal and bronchial tissue compared to epithelial expression. The expression of COX-1 and COX-2 was stronger in epithelia compared to submucosal glands. There was a similar expression of the enzymes and hbox {CysLT}_2 between upper and lower airways in all patient groups. We did not detect any significant differences between the patient groups.ConclusionsThe AA-metabolizing enzymes and the hbox {CysLT}_2 were expressed in a very similar way in different microscopic structures in samples of the upper and lower airways of individual patients. We did not detect differences between the patient groups indicating the pathogenetic role of AA metabolism in these disorders is independent of the presence of NSAR-intolerance.

Highlights

  • Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways

  • We observed a stronger expression of 5-LOX and CysLT2 in submucosal glands of nasal and bronchial tissue compared to epithelial expression

  • The expression of cyclooxygenase type 1 (COX-1) and cyclooxygenase 2 (COX-2) was stronger in epithelia compared to submucosal glands

Read more

Summary

Introduction

Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role in the pathogenesis of AERD It is still unknown, whether metabolism of AA is comparable between the upper and lower airways as well as between patients with and without NSAR intolerance. The cysteinyl leukotrienes (Cys-LTs) are metabolites produced through the 5-LOX pathway leading to bronchoconstriction, vasodilatation, mucus production and recruitment of neutrophils und eosinophils in the lung through the corresponding receptors type 1 and 2 (C ysLT2 ) [10,11,12,13,14] All these phenomena are hallmarks of severe asthma. PGE2 is a pleiotropic metabolite harboring anti-inflammatory, anti-fibrotic and immunerestrictive potential, that can at the same time mediate proinflammatory responses [15,16,17]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call